International Association for the Study of Lung Cancer

🌟 Honoring Excellence in Lung Cancer Research and Advocacy: The IASLC Lectureship & Distinguished Service Awards 🌟 The IASLC Lectureship Awards and Distinguished Service Award celebrate outstanding individuals who have made exceptional contributions to lung cancer research, advocacy, and patient care. These prestigious awards recognize those whose work is transforming the future of lung cancer treatment and improving the lives of patients worldwide. We are now accepting nominations for these honors and invite you to recognize the leaders and innovators shaping the field. Don’t miss the opportunity to celebrate their invaluable impact on the lung cancer community. Learn more and submit nominations today! Distinguished Service: https://bit.ly/4boIFtL Lectureship Awards: https://bit.ly/41muRLJ #LungCancer #ResearchExcellence #IASLC #LectureshipAwards #DistinguishedServiceAward #CancerResearch #Innovation #Leadership #Healthcare

In this episode of Lung Cancer Considered, host Dr. Narjust Florez sits down with patient advocate Summer Farmen to discuss: ✅ The power of patient education & self-advocacy ✅ The importance of seeing patients beyond their mutation ✅ The role of palliative care in lung cancer treatment Listen to Summer’s inspiring journey and the impact of patient advocacy groups. 💙🎧 🔗 Tune in here: https://bit.ly/PAGroups #LungCancer #PatientAdvocacy #LCSM #LungCancerConsidered

ICYMI: The US FDA grants fast track designation for the treatment of KRASG12C-mutant mNSCLC, while taletrectinib has been approved by China’s NMPA. More regulatory news in ILCN: https://bit.ly/3X9aosK #LCSM

TY-9591, a deuterated osimertinib derivative, demonstrated a favorable safety profile & substantial efficacy in treating EGFR-mutated #NSCLC, especially in patients w/L858R mutations in this Phase 1 dose-escalation & dose-expansion study. Learn More: https://bit.ly/4i4Ml62 #LCSM

Corey Langer, MD, illustrates the buildup, anticipation, and excitement surrounding the release of medical data. Read more in ILCN: https://bit.ly/4k2cBjx #LCSM

Calles et al. evaluated lurbinectedin + pembrolizumab in relapsed SCLC patients without prior immunotherapy. The combination showed promising efficacy, especially in platinum-sensitive patients. Read more: https://bit.ly/3Qp3xYl #LCSM

🚨 Applications are now open for the 2025 IASLC STARS PRA & Scholar Program! 🚨 If lung cancer has impacted you or a loved one, this is your chance to make a difference. The STARS (Supportive Training for Advocates on Research and Science) Program empowers advocates with the knowledge and tools to influence patient-centered research and drive meaningful change. ✅ Gain insights from global mentors ✅ Expand your advocacy impact ✅ Help shape the future of lung cancer research 📅 Applications are open Feb 3 – March 14, 2025. Apply today! ➡ bit.ly/STARSPRA25 #LungCancer #Advocacy #STARSProgram #PatientCenteredResearch

🎧 LIVE from #TTLC25 – A Must-Listen on SCLC! Small cell lung cancer (SCLC) is changing fast with new FDA approvals & emerging targeted therapies. In this episode of #LungCancerConsidered, Dr. Narjust Florez chats with Dr. Jacob Sands & Dr. Triparna Sen about: 🔹 Evolving SCLC subtypes & immune signatures 🔹 How NGS is shaping diagnosis & treatment 🔹 Understanding NSCLC transformation to SCLC Catch the latest insights on SCLC’s evolving landscape—listen now! 🎙️ https://bit.ly/TTLC25sclc #SCLC #TargetedTherapies #LungCancer #LCSM #TTLC25

Learn how the #HearHer campaign is addressing the rising incidence of lung cancer among women. Visit ILCN for more details: https://bit.ly/4bbEfX9 #LCSM

In patients with KRAS G12C-mutated non-Sq #NSCLC, sotorasib plus carboplatin/pemetrexed was found to demonstrate favorable efficacy especially in PD-L1 <1%, with manageable toxicity after an increased follow-up period. Learn More: https://bit.ly/41k4Mym #LCSM